Home / Health / Imviva Biotech Unveils Cancer Cell Therapy Breakthroughs
Imviva Biotech Unveils Cancer Cell Therapy Breakthroughs
25 Nov
Summary
- Imviva Biotech will present advanced allogeneic cell therapies.
- Presentations include CAR-T therapies for leukemia and anemia.
- Company will highlight its proprietary ANSWER platform at ASH meeting.
Imviva Biotech is poised to make significant waves at the 67th American Society of Hematology (ASH) Annual Meeting. The company will feature its cutting-edge allogeneic cell therapy candidates across multiple oral and poster presentations, detailing progress in treatments for serious blood disorders.
The focus will be on Imviva's CAR-T cell therapies, including CTD402 and CTA311, which are being developed for conditions such as severe aplastic anemia and acute lymphoblastic leukemia. These therapies represent a crucial step forward in combating these challenging hematological conditions.
Furthermore, Imviva will spotlight its proprietary ANSWER platform, designed to overcome existing obstacles in both autologous and allogeneic CAR-T cell therapy. The company's Chief Medical Officer expressed enthusiasm for sharing the platform's depth and breadth, emphasizing the breakthrough progress of CTD402 in leukemia treatment.
